Tazarotene (Synonyms: AGN 190168) |
| Catalog No.GC15459 |
Topical retinoid;antiproliferative;inducer of TIG3 tumor suppressor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 118292-40-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Tazarotene, one of the acetylenic class of retinoids, is the 3rd-generation prescription topical retinoid. It is approved for treating psoriasis, acne, and photo damaged skin [1].
Tazarotene act as a retinoid prodrug and it is converted to free acid form by rapid deesterification when used in man and animals. Tazarotenic acid shows selectivity for (RAR)-β, and (RAR)-γ though it could bind to all three classes of the retinoic acid receptor (RAR) family, and this may modify gene expression.
Tazarotene mediates these effects by regulating gene transcription. Five nonsmall cell lung carcinoma (NSCLC) cell lines and the constitutive and all-trans retinoic acid (ATRA)-inducible expression of tazarotene-induced gene3 mRNA of the five head and neck squamous cell carcinoma (HNSCC) were examined to determine whether it is associated with their responsiveness to ATRA. Consequently, ATRA induced tazarotene-induced gene3 mRNA from 6 to 12h in most of the responsive cells. Depending on the cell line, the concentration of ATRA required for induction of tazarotene-induced gene3 was ranged from 1 to 500 nm [2].
67 patients aging from 13 to 30 with facial acne attended a study to evaluate the safety and efficacy of topical tazarotene 0.1% cream in the treatment of facial acne. Patients were instructed to apply topical tazarotene cream (0.1%) as a thin film over the affected part in the evening once a day for 12 weeks. And follow-ups were done at 2nd, 4th, 8th and 12th week. As a result, 53% of the patients got remission, 9% had good response, 34% had poor response and 4% of the patients by 12 weeks of treatment was no response. Topical tazarotene cream (0.1%) is an effective and safe treatment method for the face affected by acne vulgaris [3].
References:
[1]. Orlandi A ,Bianchi L, Costanzo A, et al. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene. Journal of Investigative Dermatology, 2004, 122(4): 1037-1041.
[2]. Higuchi E, Chandraratna RAS, Hong, WK, et al. Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene, 2003, 22(30): 4627-4635.
[3]. Zakaria AS, Paul HK, Rahman MA George S K, et al. Topical tazarotene cream (0.1%) in the treatment of facial acne: an open clinical trial. Bangladesh Med Res Counc Bull, 2010, 36(2): 43-46.
| Cas No. | 118292-40-3 | SDF | |
| Synonyms | AGN 190168 | ||
| Chemical Name | ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate | ||
| Canonical SMILES | CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C | ||
| Formula | C21H21NO2S | M.Wt | 351.46 |
| Solubility | ≥ 14.85mg/mL in DMSO, ≥ 11.1 mg/mL in EtOH with ultrasonic | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8453 mL | 14.2264 mL | 28.4527 mL |
| 5 mM | 0.5691 mL | 2.8453 mL | 5.6905 mL |
| 10 mM | 0.2845 mL | 1.4226 mL | 2.8453 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: 99.95%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *